NasdaqGS - Nasdaq Real Time Price USD

Humacyte, Inc. (HUMA)

Compare

4.3400

+0.2400

(+5.85%)

At close: December 16 at 4:00:02 PM EST

4.3199

-0.02

(-0.46%)

After hours: 7:56:01 PM EST

Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference

DURHAM, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will participate in a fireside chat presentation at the Piper Sandler 36th Annual Healthcare Conference, in New York, NY on Thursday, December 5, 2024. Management will also be available for

GlobeNewswire 14 days ago

HUMA
+5.85%
HUMAW
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)

DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it will present Phase 3 results from a clinical study comparing efficacy and safety of Humacyte's acellular tissue engineered vessel (ATEV™) with autologous AV fistulas in patients with end stage renal disease at the 51st Annual Symposium on Vascular and Endovascular

GlobeNewswire 24 days ago

HUMA
+5.85%
HUMAW
Insider Buyers At Humacyte Likely Disappointed With 17% Slide

Insiders who acquired US$775.1k worth of Humacyte, Inc.'s ( NASDAQ:HUMA ) stock at an average price of US$6.64 in the...

Simply Wall St. 25 days ago

HUMA
+5.85%
HUMAW
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery

– In two studies the acellular tissue engineered vessel (ATEV) provided benefits in terms of patency, limb salvage, and infection resistance compared to current synthetic graft treatment benchmarks – – Results were published in a premier peer-reviewed surgical journal sponsored by the American Medical Association – DURHAM, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human

GlobeNewswire 25 days ago

HUMA
+5.85%
HUMAW
Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024

– sdATEVs maintained sustained patency throughout the six-month study – – sdATEV was observed to recellularize with host cells and remodel to effectively reduce the initial size mismatch between the sdATEV and the animal’s native artery – DURHAM, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced the presentation of positive preclinical

GlobeNewswire 28 days ago

HUMA
+5.85%
HUMAW
Humacyte Announces Pricing of $15.0 Million Registered Direct Offering

DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it entered into a securities purchase agreement with an institutional investor to purchase approximately $15.0 million worth of its common stock and warrants to purchase common stock in a registered direct offering. Under the terms of the securities purchase agreement

GlobeNewswire last month

HUMA
+5.85%
HUMAW
Humacyte Third Quarter 2024 Financial Results and Business Update

- FDA review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma is ongoing - - Results from the V007 Phase 3 clinical trial of the ATEV in arteriovenous (AV) access for hemodialysis patients presented at American Society of Nephrology’s Kidney Week 2024 - - Long-term results from the humanitarian program where the ATEV was used to treat vascular injuries suffered during the Ukraine conflict were presented at the U.S. Department of Defense’s foremost scientific

GlobeNewswire last month

HUMA
+5.85%
HUMAW
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024

DURHAM, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the third quarter ended September 30, 2024, on Friday, November 8, 2024. Management will host a webcast and conference call at 8:30 a.m. ET to discuss recent corporate updates from its acellular tissue engineered vessel (ATEV) programs. Title:Humacyt

GlobeNewswire last month

HUMA
+5.85%
HUMAW
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

– ATEV™ demonstrated superiority at six and 12 months (co-primary endpoints) compared to autogenous fistula, the current standard of care for hemodialysis access – - ATEV also showed superior function and patency in female, obese and diabetic patients, subgroups with historically poor outcomes with autogenous fistula procedures - DURHAM, N.C., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioen

GlobeNewswire last month

HUMA
+5.85%
HUMAW
High Growth Tech Stocks to Watch in October 2024

The United States market has remained flat over the past week but has seen a significant 40% increase over the past year, with earnings projected to grow by 15% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability, aligning with these promising market conditions.

Simply Wall St. last month

CAPR

HUMA
+5.85%
HUMAW
Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024

DURHAM, N.C., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it will host a virtual KOL event on Thursday, October 31, 2024 at 8:00 AM ET. To register, click here. The event will feature Charles Keith Ozaki, MD (Brigham and Women’s Hospital), Mohamad Anas Hussain, MD, PhD (Brigham and Women’s Hospital), and Timmy Lee, MD, MSPH

GlobeNewswire last month

HUMA
+5.85%
HUMAW
‘It’s Spare Parts for People’: Blood Vessels Grown in a Lab

Scientists have grown arteries using human cells to better treat injured patients. They have already been effective in Ukrainian soldiers.

The Wall Street Journal last month

HUMA
+5.85%
HUMAW
Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

DURHAM, N.C., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that its late-breaking abstract on the V007 Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV™) in arteriovenous access for patients with end-stage renal disease was accepted for an oral presentation at the American Society of Nephrology’s (ASN) Kidney Week

GlobeNewswire 2 months ago

HUMA
+5.85%
HUMAW
Humacyte Launches $30M Stock and Warrants Offering

Humacyte ( (HUMA) ) has shared an announcement. Humacyte, Inc. has initiated a registered direct offering of approximately $30.0 million in common stock and warrants to an institutional investor. The offering includes over 5.6 million shares and equal warrants, with an exercise price of $5.28 each. The warrants are immediately exercisable with varying expiration periods. The transaction, facilitated by EF Hutton LLC as the placement agent, is expected to close by October 7, 2024, and is part of

TipRanks 2 months ago

HUMA
+5.85%
HUMAW
Humacyte Announces Pricing of $30.0 Million Registered Direct Offering

DURHAM, N.C., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it entered into a securities purchase agreement with an institutional investor to purchase approximately $30.0 million worth of its common stock and warrants in a registered direct offering. Under the terms of the securities purchase agreement, the Company has agreed

GlobeNewswire 2 months ago

HUMA
+5.85%
HUMAW
Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024

DURHAM, N.C., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced it will host a virtual KOL event on Monday, September 30, 2024 at 8:00 AM ET. To register, click here. The event will feature Charles Fox, MD (University of Maryland School of Medicine), Rishi Kundi MD, RPVI, FACS, FSVS (University of Maryland School of Medicine), and Yin

GlobeNewswire 2 months ago

HUMA
+5.85%
HUMAW
Exploring Three High Growth Tech Stocks in the United States

The market has climbed 1.9% in the last 7 days and is up 33% over the past 12 months, with earnings expected to grow by 15% per annum over the next few years. In this favorable environment, identifying high growth tech stocks that align with these trends can be crucial for investors seeking robust returns.

Simply Wall St. 2 months ago

HUMA
+5.85%
HUMAW

ABBV
Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)

- New U.S. patent covers the design and composition of the BVP - - Positive results from ongoing preclinical studies support the potential of the BVP to deliver insulin-producing islets as a potential treatment for type 1 diabetes - DURHAM, N.C., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced the allowance of a U.S. Patent covering

GlobeNewswire 2 months ago

HUMA
+5.85%
HUMAW
Humacyte to Participate at Upcoming Investor Conferences in September

DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, and Dale Sander, Chief Financial Officer, will represent Humacyte at the following conferences in September. H.C. Wainwright 26th Annual Global Investment Conference Format: Company Present

GlobeNewswire 3 months ago

HUMA
+5.85%
HUMAW
Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program

- Results presented at the Department of Defense’s Military Health System Research Symposium (MHSRS) - - In real-world military setting the ATEV was observed to have 12-month patency of 87.1% - - There were zero instances of infection, amputation or death during the long-term follow-up period despite the severity of the wartime injuries treated - DURHAM, N.C., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally i

GlobeNewswire 3 months ago

HUMA
+5.85%
HUMAW

Performance Overview

Return	HUMA	S&P 500
YTD	+52.82%	+27.34%
1-Year	+40.45%	+28.71%
3-Year	-51.40%	+28.97%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Humacyte, Inc. (HUMA)

Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference

Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)

Insider Buyers At Humacyte Likely Disappointed With 17% Slide

Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery

Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024

Humacyte Announces Pricing of $15.0 Million Registered Direct Offering

Humacyte Third Quarter 2024 Financial Results and Business Update

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024

Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

High Growth Tech Stocks to Watch in October 2024

Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024

‘It’s Spare Parts for People’: Blood Vessels Grown in a Lab

Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

Humacyte Launches $30M Stock and Warrants Offering

Humacyte Announces Pricing of $30.0 Million Registered Direct Offering

Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024

Exploring Three High Growth Tech Stocks in the United States

Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)

Humacyte to Participate at Upcoming Investor Conferences in September

Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program

Performance Overview